The MAQC-II Project: A comprehensive study of common practices for the development and validation of microarray-based predictive models.
Leming Shi(Fudan University), Rafael A. Irizarry(Dana-Farber Cancer Institute), Dalila B. Megherbi, Miaomiao Chen(Kangwon National University), Grant R. Campbell(University of California, San Diego), Hans Bitter, Joy Linyue Fan, Sara J. Walker, Mark R. Fielden, Max Bylesjö, Lajos Pusztai(Yale Cancer Center), Weijian Chen, Song Fan, Fathi Elloumi(National Cancer Institute), Jinliang Huan, Huapan Fang, Pierre R. Bushel, Viswanath Devanarayan, Xijin Ge, Fabien Campagne, Nina Gonzaludo, Jinzhen Zhang, Rachael Thomas, David J. Dix, Benedikt Brors(German Cancer Research Center), Xiaohui Fan(Ministry of Education), André Oberthuer, Matthias Fischer, Kevin C. Dorff, Wendell Jones, Brandon D. Gallas, Cesare Furlanello(Fondazione Bruno Kessler), Joaquı́n Dopazo(Centro de Investigacion Principe Felipe), Pan Du, Richard S. Paules, Federico Goodsaid, Mingkang Wang, Mauro Delorenzi(SIB Swiss Institute of Bioinformatics), Junfen Cheng, Jutamas Shaughnessy, Deng Yuanyang, Huixiao Hong(National Center for Toxicological Research), Timothy S. Davison, Ziying Su, K. Hess, J.-H Chou, Bart Barlogie(Spanish Head & Neck Cancer Cooperative Group), Tzu‐Ming Chu, W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Unknown
January 1, 2010
Cited by 41
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
|Nature Biotechnology|2006|2.2k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k